{"transactions":[{"id":724983,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-29T20:12:40.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."}],"balance_after":26000,"derivative":{"exercise_price":34.09,"exercise_date":"2027-06-25","expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001820278-26-000008","document":"form4-06292026_080636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000182027826000008/form4-06292026_080636.xml","form_type":"4"}},{"id":728746,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T23:22:14.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":2987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date."}],"balance_after":2987,"derivative":{"exercise_price":106.52,"exercise_date":"2027-05-28","expiration_date":"2036-05-28","underlying":"Common Stock","underlying_shares":2987},"source":{"system":"sec-edgar","filing":"0001820278-26-000006","document":"form4a-06232026_110610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000182027826000006/form4a-06232026_110610.xml","form_type":"4/A","original_submission_date":"2026-06-01"}},{"id":756833,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T22:20:01.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":2987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date"}],"balance_after":2987,"derivative":{"exercise_price":53.57,"exercise_date":"2027-05-28","expiration_date":"2036-05-28","underlying":"Common Stock","underlying_shares":2987},"source":{"system":"sec-edgar","filing":"0001820278-26-000004","document":"form4-06012026_100657.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000182027826000004/form4-06012026_100657.xml","form_type":"4"}},{"id":756832,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T22:20:01.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":1878,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,609 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":24212,"source":{"system":"sec-edgar","filing":"0001820278-26-000004","document":"form4-06012026_100657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000182027826000004/form4-06012026_100657.xml","form_type":"4"}},{"id":794174,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-05-04T22:06:29.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":42105,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Denice M. Torres Revocable Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13406},"source":{"system":"sec-edgar","filing":"0001193125-26-204468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204468/ownership.xml","form_type":"4"}},{"id":794173,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T22:06:29.000Z","date":"2026-04-30","kind":"grant","planned":false,"acquired":true,"shares":12258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":12258,"derivative":{"exercise_price":18,"expiration_date":"2036-04-29","underlying":"Common Stock","underlying_shares":12258},"source":{"system":"sec-edgar","filing":"0001193125-26-204468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204468/ownership.xml","form_type":"4"}},{"id":794172,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:06:29.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":13406,"ownership":{"direct":false,"nature":"By Denice M. Torres Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":13406,"source":{"system":"sec-edgar","filing":"0001193125-26-204468","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204468/ownership.xml","form_type":"4"}},{"id":944209,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-08T00:16:27.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes2,731 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":22334,"source":{"system":"sec-edgar","filing":"0001820278-26-000002","document":"form4-01082026_120123.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000182027826000002/form4-01082026_120123.xml","form_type":"4"}},{"id":1119008,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-09T20:12:53.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such option vests in three equal annual installments beginning June 5, 2026."}],"balance_after":33000,"derivative":{"exercise_price":19.53,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001415889-25-016226","document":"form4-06092025_080642.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588925016226/form4-06092025_080642.xml","form_type":"4"}},{"id":1127389,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:41:20.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":3149,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date."}],"balance_after":3149,"derivative":{"exercise_price":94.87,"exercise_date":"2026-05-29","expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":3149},"source":{"system":"sec-edgar","filing":"0001415889-25-015167","document":"form4-06022025_080616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588925015167/form4-06022025_080616.xml","form_type":"4"}},{"id":1127388,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T20:41:20.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":2108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 4,285 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":21711,"source":{"system":"sec-edgar","filing":"0001415889-25-015167","document":"form4-06022025_080616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588925015167/form4-06022025_080616.xml","form_type":"4"}},{"id":1127387,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T20:41:20.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the\nIssuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of\nthe Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,072 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":19603,"source":{"system":"sec-edgar","filing":"0001415889-25-015167","document":"form4-06022025_080616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588925015167/form4-06022025_080616.xml","form_type":"4"}},{"id":1147586,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2025-05-15T16:33:37.000Z","date":"2025-05-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24100,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.93,"underlying":"Common Stock","underlying_shares":24100},"source":{"system":"sec-edgar","filing":"0001562180-25-003880","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218025003880/primarydocument.xml","form_type":"4"}},{"id":1147585,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T16:33:37.000Z","date":"2025-05-13","kind":"other","planned":false,"acquired":false,"shares":19510,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $5.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-25-003880","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218025003880/primarydocument.xml","form_type":"4"}},{"id":1147584,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T16:33:37.000Z","date":"2025-05-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12050,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $5.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."}],"balance_after":19510,"source":{"system":"sec-edgar","filing":"0001562180-25-003880","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218025003880/primarydocument.xml","form_type":"4"}},{"id":1482238,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-12T18:51:57.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":24100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests 100% on the earlier of June 10, 2025 or the date of the next annual meeting of stockholders of 2seventy bio, Inc."}],"balance_after":24100,"derivative":{"exercise_price":3.93,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":24100},"source":{"system":"sec-edgar","filing":"0001562180-24-005006","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218024005006/primarydocument.xml","form_type":"4"}},{"id":1482237,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-12T18:51:57.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units vest 100% on the earlier of June 10, 2025 or the date of the next annual meeting of stockholders of 2seventy bio, Inc."}],"balance_after":31560,"source":{"system":"sec-edgar","filing":"0001562180-24-005006","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218024005006/primarydocument.xml","form_type":"4"}},{"id":1494918,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T00:57:40.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":1246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date."}],"balance_after":1246,"derivative":{"exercise_price":110.7,"exercise_date":"2025-05-30","expiration_date":"2034-05-30","underlying":"Common Stock","underlying_shares":1246},"source":{"system":"sec-edgar","filing":"0001415889-24-015240","document":"form4-06042024_120636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588924015240/form4-06042024_120636.xml","form_type":"4"}},{"id":1494917,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T00:57:40.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":1716,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of\nthe Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,841 restricted stock units that have not yet vested or delivery of which has been deferred by the Reporting Person."}],"balance_after":19142,"source":{"system":"sec-edgar","filing":"0001415889-24-015240","document":"form4-06042024_120636.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588924015240/form4-06042024_120636.xml","form_type":"4"}},{"id":1571773,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T16:30:58.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1904,"price":92.3,"value":175739.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date."}],"balance_after":0,"derivative":{"exercise_price":237.7,"expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":1904},"source":{"system":"sec-edgar","filing":"0001140361-24-013934","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1771917/000114036124013934/form4.xml","form_type":"4"}},{"id":1571772,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T16:30:58.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"price":227.04,"value":1135200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":102.96,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001140361-24-013934","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1771917/000114036124013934/form4.xml","form_type":"4"}},{"id":1571771,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T16:30:58.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8500,"price":201.99,"value":1716915.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":128.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001140361-24-013934","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1771917/000114036124013934/form4.xml","form_type":"4"}},{"id":1571770,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T16:30:58.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"price":225.74,"value":5643500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":104.26,"expiration_date":"2030-12-21","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001140361-24-013934","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1771917/000114036124013934/form4.xml","form_type":"4"}},{"id":1571769,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T16:30:58.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":990,"price":330,"value":326700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013934","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1771917/000114036124013934/form4.xml","form_type":"4"}},{"id":1687287,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-04T21:42:54.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6.726 restricted stock units that have not yet vested or delivery of which has been deferred by the Reporting Person."}],"balance_after":17426,"source":{"system":"sec-edgar","filing":"0001415889-24-000632","document":"form4-01042024_090140.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588924000632/form4-01042024_090140.xml","form_type":"4"}},{"id":1846082,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2023-06-22T16:03:11.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":1904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates."}],"balance_after":1904,"derivative":{"exercise_price":237.7,"expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":1904},"source":{"system":"sec-edgar","filing":"0000950170-23-029393","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1771917/000095017023029393/ownership.xml","form_type":"4"}},{"id":1846081,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-22T16:03:11.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Comprised of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates."}],"balance_after":990,"source":{"system":"sec-edgar","filing":"0000950170-23-029393","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1771917/000095017023029393/ownership.xml","form_type":"4"}},{"id":1854622,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T17:03:08.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":16900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests 100% on the earlier of June 13, 2024 or the date of the next annual meeting of stockholders of 2seventy bio, Inc."}],"balance_after":16900,"derivative":{"exercise_price":11.81,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":16900},"source":{"system":"sec-edgar","filing":"0001562180-23-005222","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218023005222/primarydocument.xml","form_type":"4"}},{"id":1854621,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T17:03:08.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":8400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units vest 100% on the earlier of June 13, 2024 or the date of the next annual meeting of stockholders of 2seventy bio, Inc."}],"balance_after":19510,"source":{"system":"sec-edgar","filing":"0001562180-23-005222","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218023005222/primarydocument.xml","form_type":"4"}},{"id":1866579,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-06T00:15:01.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":3230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a grant of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,195 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":16531,"source":{"system":"sec-edgar","filing":"0001415889-23-009295","document":"form4-06062023_120658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588923009295/form4-06062023_120658.xml","form_type":"4"}},{"id":2066389,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T01:10:02.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":1572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the\nIssuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of\nthe Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 7,990 restricted stock units that have not vested or been delivered to the Reporting Person."}],"balance_after":13301,"source":{"system":"sec-edgar","filing":"0001415889-23-000469","document":"form4-01052023_010148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588923000469/form4-01052023_010148.xml","form_type":"4"}},{"id":2229410,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-06-16T16:41:37.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 15, 2023, and (ii) the 2023 annual meeting of the Issuer's stockholders."}],"balance_after":5000,"derivative":{"exercise_price":102.96,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001593968-22-001151","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1771917/000159396822001151/primary_01.xml","form_type":"4"}},{"id":2236077,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T20:00:41.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."}],"balance_after":24000,"derivative":{"exercise_price":2.01,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-22-036149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919122036149/doc4.xml","form_type":"4"}},{"id":2237988,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-09T18:20:27.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":16900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests 100% on the earlier of June 8, 2023 or the date of the next annual meeting of stockholders of 2seventy bio, Inc."}],"balance_after":16900,"derivative":{"exercise_price":13.51,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":16900},"source":{"system":"sec-edgar","filing":"0001562180-22-004993","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218022004993/primarydocument.xml","form_type":"4"}},{"id":2237987,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-09T18:20:27.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units vest 100% on the earlier of June 8, 2023 or the date of the next annual meeting of stockholder of 2seventy bio, Inc."}],"balance_after":11110,"source":{"system":"sec-edgar","filing":"0001562180-22-004993","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218022004993/primarydocument.xml","form_type":"4"}},{"id":2241580,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T23:54:29.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":4364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a grant of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,255 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":11729,"source":{"system":"sec-edgar","filing":"0001104659-22-068666","document":"tm2217841-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000110465922068666/tm2217841-4_4seq1.xml","form_type":"4"}},{"id":2443244,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T01:58:17.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":1455,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a grant of restricted stock units received by the reporting person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,916 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":7365,"source":{"system":"sec-edgar","filing":"0001104659-22-001664","document":"tm221974-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000110465922001664/tm221974-4_4seq1.xml","form_type":"4"}},{"id":2444113,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-05T18:00:17.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in 36 equal monthly installments following December 9, 2021, so long as the grantee remains a director or other service provider of the Company on such dates."}],"balance_after":12000,"derivative":{"exercise_price":5.08,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-22-001905","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919122001905/doc4.xml","form_type":"4"}},{"id":2506751,"issuer":{"id":78923,"kind":"organization","name":"bluebird bio, Inc.","symbol":"BLUE"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-17T08:55:27.000Z","date":"2021-11-11","kind":"disposition_to_issuer","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3."},{"field":"shares","element":"transactionShares","label":"F6","text":"Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3."}],"balance_after":0,"derivative":{"exercise_price":0,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0001628280-21-023643","document":"wf-form4_163715731476743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293971/000162828021023643/wf-form4_163715731476743.xml","form_type":"4"}},{"id":2506750,"issuer":{"id":78923,"kind":"organization","name":"bluebird bio, Inc.","symbol":"BLUE"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-17T08:55:27.000Z","date":"2021-11-11","kind":"disposition_to_issuer","acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on August 10, 2020 and vests ratably over three years in annual installments commencing on August 10, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on August 10, 2020 and vests ratably over three years in annual installments commencing on August 10, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on August 10, 2020 and vests ratably over three years in annual installments commencing on August 10, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3."}],"balance_after":4430,"derivative":{"exercise_price":32.76,"expiration_date":"2030-08-10","underlying":"Common Stock","underlying_shares":4430},"source":{"system":"sec-edgar","filing":"0001628280-21-023643","document":"wf-form4_163715731476743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293971/000162828021023643/wf-form4_163715731476743.xml","form_type":"4"}},{"id":2506749,"issuer":{"id":78923,"kind":"organization","name":"bluebird bio, Inc.","symbol":"BLUE"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-17T08:55:27.000Z","date":"2021-11-11","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading \"regular way\") on the five trading days immediately prior to the distribution date (the \"bluebird Pre-Distribution VWAP\") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading \"regular way\") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading \"regular way\") on the five trading days immediately following the distribution date (the \"bluebird Post-Distribution VWAP\")."},{"field":"security","element":"securityTitle","label":"F3","text":"bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP."},{"field":"security","element":"securityTitle","label":"F4","text":"Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders."}],"balance_after":2726,"source":{"system":"sec-edgar","filing":"0001628280-21-023643","document":"wf-form4_163715731476743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293971/000162828021023643/wf-form4_163715731476743.xml","form_type":"4"}},{"id":2506748,"issuer":{"id":78923,"kind":"organization","name":"bluebird bio, Inc.","symbol":"BLUE"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-17T08:55:27.000Z","date":"2021-11-11","kind":"other","acquired":true,"shares":1476,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units awarded to the reporting person prior to the separation (the \"Separation\") of 2seventy bio, Inc. (\"2seventy\") from bluebird bio, Inc. (\"bluebird\"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the \"EMA\") such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on August 10, 2020 and vests ratably over three years in annual installments commencing on August 10, 2021."},{"field":"security","element":"securityTitle","label":"F2","text":"bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading \"regular way\") on the five trading days immediately prior to the distribution date (the \"bluebird Pre-Distribution VWAP\") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading \"regular way\") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading \"regular way\") on the five trading days immediately following the distribution date (the \"bluebird Post-Distribution VWAP\")."},{"field":"security","element":"securityTitle","label":"F3","text":"bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP."}],"balance_after":2726,"source":{"system":"sec-edgar","filing":"0001628280-21-023643","document":"wf-form4_163715731476743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293971/000162828021023643/wf-form4_163715731476743.xml","form_type":"4"}},{"id":2511012,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-16T06:49:20.000Z","date":"2021-11-11","kind":"grant","acquired":true,"shares":3219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders (see footnotes 2 and 3)."}],"balance_after":3219,"derivative":{"exercise_price":50.98,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":3219},"source":{"system":"sec-edgar","filing":"0001628280-21-023474","document":"wf-form4_163706330477659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000162828021023474/wf-form4_163706330477659.xml","form_type":"4"}},{"id":2511011,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-16T06:49:20.000Z","date":"2021-11-11","kind":"grant","acquired":true,"shares":1476,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option vests ratably over three years in annual installments commencing on August 10, 2020 (see footnotes 2 and 3)."}],"balance_after":1476,"derivative":{"exercise_price":102.14,"expiration_date":"2030-08-10","underlying":"Common Stock","underlying_shares":1476},"source":{"system":"sec-edgar","filing":"0001628280-21-023474","document":"wf-form4_163706330477659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000162828021023474/wf-form4_163706330477659.xml","form_type":"4"}},{"id":2511010,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T06:49:20.000Z","date":"2021-11-11","kind":"grant","acquired":true,"shares":2002,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading \"regular way\") on the five trading days immediately prior to the distribution date (the \"bluebird Pre-Distribution VWAP\"), the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading \"regular way\") on the five trading days immediately following the distribution date (the \"2seventy VWAP\") multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird common stock (trading \"regular way\") on the five trading days immediately following the distribution date (the \"bluebird Post-Distribution VWAP\")."},{"field":"security","element":"securityTitle","label":"F3","text":"The number of shares underlying the converted 2seventy equity awards was determined by multiplying the number of shares underlying the existing bluebird equity awards by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the sum of (1) the 2seventy VWAP multiplied by the distribution ratio and (2) the quotient obtained by dividing the bluebird Post-Distribution VWAP by the distribution ratio. bluebird equity awards granted on or after January 1, 2021, such equity awards were converted into 2seventy equity awards. The number of shares of 2seventy common stock underlying such converted equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the 2seventy VWAP."},{"field":"security","element":"securityTitle","label":"F4","text":"In connection with the Separation, the reporting person received restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnotes 2 and 3). This restricted stock unit award vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 416 shares of 2seventy's common stock received in a pro rata distribution by bluebird as a result of the Separation."}],"balance_after":2910,"source":{"system":"sec-edgar","filing":"0001628280-21-023474","document":"wf-form4_163706330477659.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000162828021023474/wf-form4_163706330477659.xml","form_type":"4"}},{"id":2511009,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T06:49:20.000Z","date":"2021-11-11","kind":"grant","acquired":true,"shares":492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"In connection with the separation (the \"Separation\") of seventy bio, Inc. (\"2seventy\") from bluebird bio, Inc. (\"bluebird\"), the reporting person received restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnotes 2 and 3). This restricted stock unit award vests ratably over three years in annual installments commencing on August 10, 2020."},{"field":"security","element":"securityTitle","label":"F2","text":"bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading \"regular way\") on the five trading days immediately prior to the distribution date (the \"bluebird Pre-Distribution VWAP\"), the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading \"regular way\") on the five trading days immediately following the distribution date (the \"2seventy VWAP\") multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird common stock (trading \"regular way\") on the five trading days immediately following the distribution date (the \"bluebird Post-Distribution VWAP\")."},{"field":"security","element":"securityTitle","label":"F3","text":"The number of shares underlying the converted 2seventy equity awards was determined by multiplying the number of shares underlying the existing bluebird equity awards by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the sum of (1) the 2seventy VWAP multiplied by the distribution ratio and (2) the quotient obtained by dividing the bluebird Post-Distribution VWAP by the distribution ratio. bluebird equity awards granted on or after January 1, 2021, such equity awards were converted into 2seventy equity awards. The number of shares of 2seventy common stock underlying such converted equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the 2seventy VWAP."}],"balance_after":492,"source":{"system":"sec-edgar","filing":"0001628280-21-023474","document":"wf-form4_163706330477659.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000162828021023474/wf-form4_163706330477659.xml","form_type":"4"}},{"id":2617840,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-03T16:16:02.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest ratably over three years following July 6, 2021, so long as the grantee remains a director or other service provider of the Company on such dates."}],"balance_after":36000,"derivative":{"exercise_price":6.1,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001209191-21-049302","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919121049302/doc4.xml","form_type":"4"}},{"id":2656671,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-06-23T16:37:55.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 16, 2022, and (ii) the 2022 annual meeting of the Issuer's stockholders."}],"balance_after":8500,"derivative":{"exercise_price":128.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001593968-21-001687","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1771917/000159396821001687/primary_01.xml","form_type":"4"}},{"id":2663359,"issuer":{"id":78923,"kind":"organization","name":"bluebird bio, Inc.","symbol":"BLUE"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T16:10:25.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders."}],"balance_after":5000,"derivative":{"exercise_price":32.83,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-21-004355","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293971/000156218021004355/primarydocument.xml","form_type":"4"}},{"id":2663358,"issuer":{"id":78923,"kind":"organization","name":"bluebird bio, Inc.","symbol":"BLUE"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-17T16:10:25.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":3109,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units for common stock vest 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders."}],"balance_after":5859,"source":{"system":"sec-edgar","filing":"0001562180-21-004355","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293971/000156218021004355/primarydocument.xml","form_type":"4"}},{"id":2679016,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-07T22:48:19.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":2382,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,461 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":5910,"source":{"system":"sec-edgar","filing":"0001104659-21-077831","document":"tm2119039-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000110465921077831/tm2119039-3_4seq1.xml","form_type":"4"}},{"id":2812245,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-03T23:59:32.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents a grant of restricted stock units received by the reporting person as the prorated portion of the annual equity grant upon appointment to the Issuer's Board of Directors pursuant to the Issuer's Director Compensation Policy. These restricted stock units vest on June 3, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":3528,"source":{"system":"sec-edgar","filing":"0001104659-21-031657","document":"tm218619-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000110465921031657/tm218619-3_4seq1.xml","form_type":"4"}},{"id":2812244,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-03T23:59:32.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":3079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a grant of restricted stock units received by the reporting person as an initial equity grant upon appointment to the Issuer's Board of Directors, pursuant to the Issuer's Director Compensation Policy. One-third of the restricted stock units vest on each of the first three anniversaries of the grant date, and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":3079,"source":{"system":"sec-edgar","filing":"0001104659-21-031657","document":"tm218619-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000110465921031657/tm218619-3_4seq1.xml","form_type":"4"}},{"id":2934066,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-22T17:14:31.000Z","date":"2020-12-22","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in thirty-six equal monthly installments beginning on December 22, 2020."}],"balance_after":25000,"derivative":{"exercise_price":104.26,"expiration_date":"2030-12-21","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-20-034850","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1771917/000089924320034850/doc4.xml","form_type":"4"}},{"id":3061724,"issuer":{"id":78923,"kind":"organization","name":"bluebird bio, Inc.","symbol":"BLUE"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-08-11T16:21:32.000Z","date":"2020-08-10","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests ratably over three years in annual installments commencing on August 10, 2020."}],"balance_after":4500,"derivative":{"exercise_price":65.77,"expiration_date":"2030-08-10","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001562180-20-005392","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293971/000156218020005392/primarydocument.xml","form_type":"4"}},{"id":3061723,"issuer":{"id":78923,"kind":"organization","name":"bluebird bio, Inc.","symbol":"BLUE"},"owners":[{"id":35025,"kind":"person","name":"Torres Denice","position":1,"cik":"0001820278","reported_name":"Torres Denice","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-11T16:21:32.000Z","date":"2020-08-10","kind":"grant","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units for common stock vest ratably over three years in annual installments commencing on August 10, 2020."}],"balance_after":2750,"source":{"system":"sec-edgar","filing":"0001562180-20-005392","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293971/000156218020005392/primarydocument.xml","form_type":"4"}}]}